Clinical Trials · NCT07816744

Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression

Not Yet RecruitingN/ASemaglutide (Investigational)
Phase
N/A
Recruitment status
Not Yet Recruiting
Sponsor
Axel Brandes
Enrollment
480
Start date
Oct 2026
Locations
2 sites, Denmark
Primary endpoint
Hierarchical composite outcome capturing AF progression and AF burden, inte-grating clinical events assessed by blinded adjudication and objective measures of AF burden, assessed by 14-day continuous ECG monitoring
View Semaglutide compound reference